Subcutaneous · GLP-1 agonist
Vurolenatide
2 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
0
Sites
7
Countries
1
Endpoints
5
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1/2
1
Phase 2
1
Trials by status
Terminated
1
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
2
Other (unclassified)
2
Patient-reported / QoL
1
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04988997VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome. | Vurolenatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | - | Ph 2 | Terminated | 6 | Aug 2022 | - | |
| NCT04379856Proof of Concept Study in Patients With Short Bowel Syndrome | Exenatide, Vurolenatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | - | Ph 1/2 | Unknown | 1 | Dec 2020 | - |
Showing 1-2 of 2 trials